The deal will give Pilot Chemicals a much improved footprint in the Mexico, Central American and South American markets for growth opportunities in the surfactants and antimicrobial business, much of which lays within the personal care arena.
According to Pillot Chemical executives, the deal is a part of the company’s strategy to increase growth and innovation, which will be achieved through the diversification of its international business and providing a platform for further growth in Latin America.
Expansion of R&D capabilities
The deal will also enable Pilot Chemical to expand its Good Manufacturing Practice testing and research and development capabilities, thanks to Órgano Síntesis existing facilities.
The deal will means that Órgano Síntesis, which trades under the acronym OSSA, will retain its name under the leadership of Pilot’s management.
Likewise, Frederico Soto, director general of OSSA’s group operations for the past 17 years, will remain in this position, reporting directly to Mike Clark, president and chief operation officer of Pilot Chemical.
The acquisition will also include OSSA’s workforce of nearly 100 people, as well as its production site at Toluca and its headquarters in Mexico City.
Enhancing growth and innovation
In reaching the acquisition agreement, the management of both companies believe that the resulting synergies will significantly both businesses, ultimately leading to further growth.
“Today marks an important milestone for Pilot. OSSA greatly enhances our opportunities for growth and allows for further expansion into new technologies and manufacturing capabilities,” said Clark.
“It has an outstanding reputation in the marketplace, and together we are well positioned for the future.”